CDCP1 and breast neoplasm: To study whether CD6 loss was also detected in vivo, CD318 expression patterns and CD6+ lymphocytic infiltrate on tumors were evaluated by IHC using tissue microarrays (TMA) containing breast tumor samples from 117 patients.